Get updates delivered to you daily. Free and customizable.
BioMed Central
Modelling the potential clinical and economic impact of universal immunisation with nirsevimab versus standard of practice for protecting all neonates and infants in their first respiratory syncytial virus season in Spain
By Ruth Gil-Prieto,
2 days agoBy Ruth Gil-Prieto,
2 days agoRead in NewsBreak
Comments / 0
Add a Comment
YOU MAY ALSO LIKE
Denver, CO23 hours ago
Kentucky State23 hours ago
Louisville, KY3 days ago
BioMed Central2 days ago
Georgia State17 days ago
Rushville, MO17 days ago
Massachusetts State12 days ago
Devra Lee2 hours ago
Get updates delivered to you daily. Free and customizable.
It’s essential to note our commitment to transparency:
Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. As a platform hosting over 100,000 pieces of content published daily, we cannot pre-vet content, but we strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation.
Comments / 0